SRCIN1 and breast carcinoma: These data highlight that in ERBB2 tumours, amplification of the ERBB2 locus may lead to SRCIN1 amplification or loss, thus contributing to the biological heterogeneity of this breast cancer subgroup7, 8, 9, 10, 11.